文献速递浆细胞疾病造血干细胞移植与细胞治疗

西达基奥仑赛在多发性骨髓瘤患者经其他BCMA靶向药物治疗后进展中的疗效与安全性

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents.
PubMed 文献 · Blood · 2023-01-01

CARTITUDE-2为2期多队列研究,评估西达基奥仑赛(cilta-cel)在经蛋白酶体抑制剂、免疫调节药、抗CD38抗体及非细胞性抗BCMA免疫治疗失败的多发性骨髓瘤患者中的安全性与疗效。20例患者接受单次输注,中位随访11.3个月,总缓解率60.0%(95%CI 36.1-80.9),7例(35%)达MRD阴性。

要点

  • 经非细胞性抗BCMA治疗进展后,西达基奥仑赛总缓解率60.0%,MRD阴性率35%。
  • 细胞因子释放综合征发生率60%,均为1-2级;无帕金森综合征发生。
  • 7例(35%)死亡,其中3例疾病进展,4例不良事件(1例治疗相关、3例无关)。

核心结论

  • 西达基奥仑赛在既往接受过抗BCMA治疗且其他疗法耗尽的复发/难治性多发性骨髓瘤患者中诱导了良好的缓解。

研究设计与样本

  • CARTITUDE-2为2期多队列研究,队列C纳入经蛋白酶体抑制剂、免疫调节药物、抗CD38抗体及非细胞性抗BCMA免疫治疗后进展的患者。
  • 共20例患者接受单次西达基奥仑赛输注(13例暴露于抗体药物偶联物,7例暴露于双特异性抗体,其中1例抗体药物偶联物组患者既往也暴露于双特异性抗体)。
  • 主要终点为10⁻⁵灵敏度下的微小残留病(MRD)阴性。

主要发现

  • 中位随访11.3个月(范围0.6-16.0),20例中7例(35%)MRD阴性,MRD可评估亚组10例中7例(70.0%)MRD阴性。
  • 总缓解率(95%CI)为60.0%(36.1-80.9)。
  • 中位缓解持续时间(95%CI)为11.5个月(7.9-不可估计),中位无进展生存期(95%CI)为9.1个月(1.5-不可估计)。
  • 细胞因子释放综合征发生于12例(60%)患者,均为1-2级;4例发生免疫效应细胞相关神经毒性综合征(2例为3-4级);无帕金森综合征发生。
  • 7例(35%)患者死亡,其中3例死于疾病进展,4例死于不良事件(1例治疗相关,3例无关)。

关键数值与推荐

  • 16例(80%)对既往抗BCMA治疗难治。
  • 最常见的不良事件为血液学不良事件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

B-cell maturation antigen (BCMA)-targeting therapies, including bispecific antibodies (BsAbs) and antibody-drug conjugates (ADCs), are promising treatments for multiple myeloma (MM), but disease may progress after their use. CARTITUDE-2 is a phase 2, multicohort study evaluating the safety and efficacy of cilta-cel, an anti-BCMA chimeric antigen receptor T therapy, in various myeloma patient populations. Patients in cohort C progressed despite treatment with a proteasome inhibitor, immunomodulatory drug, anti-CD38 antibody, and noncellular anti-BCMA immunotherapy. A single cilta-cel infusion was given after lymphodepletion. The primary end point was minimal residual disease (MRD) negativity at 10-5. Overall, 20 patients were treated (13 ADC exposed; 7 BsAb exposed; 1 in the ADC group also had prior BsAb exposure). Sixteen (80%) were refractory to prior anti-BCMA therapy. At a median follow-up of 11.3 months (range, 0.6-16.0), 7 of 20 (35%) patients were MRD negative (7 of 10 [70.0%] in the MRD-evaluable subset). Overall response rate (95% confidence interval [CI]) was 60.0% (36.1-80.9). Median duration of response and progression-free survival (95% CI) were 11.5 (7.9-not estimable) and 9.1 (1.5-not estimable) months, respectively. The most common adverse events were hematologic. Cytokine release syndrome occurred in 12 (60%) patients (all grade 1-2); 4 had immune effector cell-associated neurotoxicity syndrome (2 had grade 3-4); none had parkinsonism. Seven (35%) patients died (3 of progressive disease, 4 of adverse events [1 treatment related, 3 unrelated]). Cilta-cel induced favorable responses in patients with relapsed/refractory MM and prior exposure to anti-BCMA treatment who had exhausted other therapies. This trial was registered at www.clinicaltrials.gov as NCT04133636.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Cohen AD, Mateos MV, Cohen YC, et al. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. Blood. 2023. PMID: 36095849. doi:10.1182/blood.2022015526

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。